Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood pressure in the arteries to the lungs, rapidly evolving in a clinical syndrome of dyspnoea and fatigue and eventually leading to right ventricular failure and death. MedDRA version: 13.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Conditions
Interventions
Trade Name: Qutenza
Product Name: Qutenza
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Capsaicin
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 179-
Sponsors
Imperial College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Male or female patients 18 years or older with symptomatic PAH. 2.Willing to provide written informed consent to participate in the study. 3.With documented diagnosis of PAH, either idiopathic, familial or associated with connective tissue disease, congenital heart disease or the use of anorexogenic drugs. 4.Documented haemodynamic diagnosis of PAH by right heart catheterization – performed at any time prior to screening, showing: mean pulmonary arterial pressure >25 mm Hg, pulmonary capillary wedge pressure =/240 dynes/sec/cm5. 5.Receiving stable doses of Remodulin® SC, continuously infused at a dose of at least 2.5 ng/kg/min for at least 8 weeks prior to enrolment. Additional medications that are approved for treatment of PAH (either bosentan or sildenafil) and other supplementary treatments such as oral anticoagulants, diuretics, digitalis, calcium channel blockers or oxygen supplementation are permitted. 6.History of pain at the site of Remodulin® SC infusion for at least 8 weeks prior to enrolment and as assessed on the 11 point pain intensity numerical pain rating scale (NPRS) from 0 to 10, where 0 represents “No pain" and 10 represents “Maximum pain imaginable”. Patients with a history of pain intensity equal or greater than 3 NPRS points (as determined by the NPRS trial diary completed during the screening period) are eligible to participate. [The use of systemic analgesics to relieve pain at the site of Remodulin® SC infusion, including salicylates, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, as well as topical analgesic-containing gels or creams (such as capsaicin 0.025% and 0.075% cream) and local anesthetics such as lidocaine are also permitted providing they remain unchanged for the entire duration of the study (i.e. from screening to the end of study follow up visit).] 7.Modified New York Heart Association (NYHA) (WHO) classification II-IV that has been stable for at least 8 weeks prior to enrolment. 8.A female subject is eligible to participate if she is of: •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1.Patient’s participating in another clinical trial or who have done so within 30 days before screening. 2.Patients with PAH in NYHA/WHO functional class I at screening. 3.Known to be positive for human immunodeficiency virus (HIV). 4.Patients with any additional medical condition or illness that, in the opinion of the Investigator would interfere with study compliance and/or impair the patient's ability to participate or complete the study. Concurrent diseases or conditions that may interfere with study participation or safety include bleeding disorders, arrhythmias, organ transplant, organ failure, current neoplasm, poorly controlled diabetes mellitus, poorly controlled hypertension, clinically significant haematological or biochemical abnormality, and serious neurological disorders. 5.Patients with a history of substance abuse (e.g. alcohol or drug abuse) within the previous 6 months before enrolment. 6.Patients with a history of severe allergies or multiple drug allergies and/or reported hypersensitivity to capsaicin. 7.Patients with no history of pain at the site of Remodulin® SC infusion or average pain intensity at screening less than 3 points on the numerical pain rating scale (NPRS). 8.Life expectancy less than 12 months. 9.Unable to provide informed consent. 10.Female patients who are lactating or pregnant (positive pre-randomisation serum pregnancy test) or plan to become pregnant during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objectives of this study are to determine: 1.The safety and tolerability of a single application of Qutenza® (capsaicin 8% patch) in pulmonary arterial hypertension patients. 2. The efficacy of a single application of Qutenza® (capsaicin 8% patch) in improving site pain caused by continuous SC infusion of Remodulin® in pulmonary arterial hypertension patients, relative to transparent adhesive control dressing (Tegaderm film 10cmx12cm) in combination with 0.075% capsaicin cream (Axsain®), as assessed by the change in Numerical Pain Rating Scale (NPRS) from baseline.;Secondary Objective: The secondary objective of this study is to determine: The efficacy of a single application of Qutenza® (capsaicin 8% patch) in reducing site pain caused by continuous SC infusion of Remodulin®, in pulmonary arterial hypertension patients, relative to transparent adhesive control dressing (Tegaderm film 10cmx12cm) in combination with 0.075% capsaicin cream (Axsain®), as assessed by: Patient Global Impression of Change (PGIC) relative to Remodulin® SC repositioning on the day of screening. The change in area of cutaneous hypersensitivity around the infusion site (optional and when feasible) [assessed using 1) cotton wool, 2) brush, 3) monofilaments, 4) pin prick and 5) thermal thresholds], relative to Remodulin® SC repositioning on the day of screening. The reduction in area of skin axon reflex vasodilatation (skin flare) around the infusion site (optional and when feasible) [assessed using 1) visual tracing of area of redness, and 2) laser Doppler fluxmetry], relative to Remod;Primary end point(s): The primary outcome measure of safety will be based on the incidence, intensity and type of AEs and clinically significant changes in vital signs (pulse rate, blood pressure, respiration rate, pulse oximetry and temperature), and changes in concomitant medications throughout the study. Evaluation of safety will also be based on subject’s physical examinat | — |
Countries
United Kingdom
Outcome results
None listed